再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ZLAB 再鼎医药

盘前交易 07-09 05:18:00 EDT

19.75

+0.40

+2.07%

盘前19.75

+0.000.00%

04:24 EDT

最高19.83	最低18.95	成交量135.37万
今开19.40	昨收19.35	日振幅4.54%
总市值22.19亿	流通市值21.60亿	总股本1.12亿
成交额2,624万	换手率1.24%	流通股本1.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ZLAB","market":"US","secType":"STK","nameCN":"再鼎医药","latestPrice":19.75,"timestamp":1783540800000,"preClose":19.35,"halted":0,"volume":1353736,"hourTrading":{"tag":"盘前","latestPrice":19.75,"preClose":19.75,"latestTime":"04:24 EDT","volume":138,"amount":2714.7600119999997,"timestamp":1783585486468,"change":0,"changeRate":0,"amplitude":0.021772},"delay":0,"changeRate":0.020671834625322922,"floatShares":109371942,"shares":112353700,"eps":-1.6209,"marketStatus":"盘前交易","change":0.4,"latestTime":"07-09 05:18:00 EDT","open":19.4,"high":19.83,"low":18.952,"amount":26236559.770544,"amplitude":0.045375,"askPrice":21.71,"askSize":100,"bidPrice":19.45,"bidSize":111,"shortable":3,"etf":0,"ttmEps":-1.6209,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783603800000},"marketStatusCode":1,"adr":1,"adrRate":10,"listingDate":1505880000000,"exchange":"NASDAQ","adjPreClose":19.75,"preHourTrading":{"tag":"盘前","latestPrice":19.75,"preClose":19.75,"latestTime":"04:24 EDT","volume":138,"amount":2714.7600119999997,"timestamp":1783585486468,"change":0,"changeRate":0,"amplitude":0.021772},"postHourTrading":{"tag":"盘后","latestPrice":19.75,"preClose":19.75,"latestTime":"19:16 EDT","volume":19288,"amount":381620.0754,"timestamp":1783552585042,"change":0,"changeRate":0,"amplitude":0.014177},"volumeRatio":2.282823664057118,"impliedVol":0.9375,"impliedVolPercentile":0.892},"requestUrl":"/m/hq/s/ZLAB","defaultTab":"news","newsList":[{"id":"2645408024","title":"再鼎医药(09688)授出受限制股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2645408024","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2645408024?lang=zh_cn&edition=full","pubTime":"2026-06-22 20:05","pubTimestamp":1782129907,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于2026年6月17日(美国东部时间)根据2024年股权激励计划获授人授出部分受限制股份。所授出受限制股份数目(以美国存托股份计)：178,968。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1457113.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4588","BK1161","ZLAB","BK4548","BK4585","BK1574","LU2488822045.USD","09688","BK4139","BK4526","BK1588","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644314776","title":"创新药概念普涨 再鼎医药(09688)升逾6% 机构指该板块仍将为行业核心增量","url":"https://stock-news.laohu8.com/highlight/detail?id=2644314776","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644314776?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:21","pubTimestamp":1781749308,"startTime":"0","endTime":"0","summary":"金吾财讯 | 港股创新药概念普涨，截至发稿，再鼎医药 涨6.34%，康方生物涨5.96%，药明康德涨3.59%，康诺亚-B涨3.49%，亚盛医药涨3.45%，药明生物涨3.08%，金斯瑞生物科技涨2.93%，百济神州涨2.60%。华鑫证券研究称，自2015年创新药审批改革开始，创新药逐步成为医药行业的核心增量。6月份以来，已有药明康德等企业开始公告回购或增持方案，逐步扭转市场对医药行业的信心。","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MGQ5MWNhYjgxMjA0ZDU3OGI4Y2EzYTk1OWIyNGM1NTg2NTUyNjEzMTk5Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1984066","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1589","SG9999002463.SGD","LU0456846285.SGD","LU0516422952.EUR","LU2242644610.SGD","159992","02359","06160","LU0307460666.USD","LU2328871848.SGD","HK0000306685.HKD","LU0140636845.USD","BK1587","01548","LU2488822045.USD","BK1583","ZLAB","LU1719994722.HKD","LU1303224171.USD","02162","BK1588","09926","LU2045819591.USD","IE00BPRC5H50.USD","BK1141","LU0348827113.USD","BK1161","LU0516423174.USD","BK4526","HK0000306701.USD","LU1794554557.SGD","LU1961090484.USD","LU0561508036.HKD","LU0348784397.USD","LU1720050803.USD","LU0979878070.USD","LU0516422366.SGD","LU0326950275.SGD","LU0516423091.SGD","06855","LU1969619763.USD","LU0588546209.SGD","HK0000320223.HKD","BK1521","LU2476274308.USD","02269","BK4531","LU0417516571.SGD","06978","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177778204","title":"港股创新药概念股盘中走高！再鼎医药涨超6%，康方生物涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1177778204","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177778204?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:20","pubTimestamp":1781749207,"startTime":"0","endTime":"0","summary":"6月18日，港股创新药概念股盘中走高，$再鼎医药(ZLAB)$涨超6%，$康方生物(09926)$涨超5%，$亚盛医药(06855)$、$百济神州(06160)$、$药明生物(02269)$、$药明康德(02359)$涨超3%。","market":"hk","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1961090484.USD","LU0561508036.HKD","LU2476274308.USD","BK1574","BK4548","06978","IE00B543WZ88.USD","LU0348767384.USD","LU2778985437.USD","LU0348827113.USD","BK4531","LU0417516738.SGD","BK4139","LU0417516902.SGD","LU0540923850.HKD","LU0348735423.USD","BK4585","BK4526","LU0348825331.USD","LU0348784397.USD","LU0634319403.HKD","LU1720050803.USD","LU2399975544.HKD","BK4588","BK1588","159992","09688","LU0417516571.SGD","LU2488822045.USD","BK1161","LU2476274720.SGD","LU1794554557.SGD","VXUS","ZLAB","LU0348766576.USD","LU0348783233.USD","IE00B5MMRT66.SGD","IE00BPRC5H50.USD","09926"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2644776521","title":"港股异动 | 再鼎医药(09688)逆市涨超7% 近日Zoci获欧洲药品管理局孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2644776521","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2644776521?lang=zh_cn&edition=full","pubTime":"2026-06-18 10:19","pubTimestamp":1781749159,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药逆市涨超7%，截至发稿，涨6.27%，报14.4港元，成交额7254.49万港元。消息面上，近日，据再鼎医药官微消息，公司宣布，欧洲药品管理局已授予具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan孤儿药资格认定，用于治疗来源于肺的神经内分泌癌。此前，美国FDA已授予zoci用于治疗小细胞肺癌的快速通道资格认定及孤儿药资格认定。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1455952.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09688","LU2488822045.USD","BK4531","BK1588","BK4139","BK1161","BK1574","BK4585","ZLAB","BK4588","BK4548","VXUS","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642144385","title":"港股异动 | 再鼎医药(09688)涨超4% 精神分裂创新药凯捷乐®上市 宫颈癌新药在华获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2642144385","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642144385?lang=zh_cn&edition=full","pubTime":"2026-06-10 14:46","pubTimestamp":1781074008,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药涨超4%，截至发稿，涨4.06%，报13.07港元，成交额1.56亿港元。当天，该药在首都医科大学附属北京安定医院开出全国首张处方，并于同日惠及全国30余个城市、近50家医院的精神分裂症患者。此外，再鼎医药日前宣布，国家药品监督管理局已批准缇乐的生物制品上市许可申请，用于治疗化疗期间或之后出现进展的复发或转移性宫颈癌成人患者。维替索妥尤单抗在全球3期innovaTV301临床研究中展现出了显著的统计学意义总生存获益。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1452468.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK4585","06978","09688","IPOS","LU2488822045.USD","VXUS","BK4588","BK4531","BK4526","159992","BK4139","BK4548","ZLAB","BK1161","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640020489","title":"再鼎医药(09688)授出5000份受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2640020489","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2640020489?lang=zh_cn&edition=full","pubTime":"2026-06-03 21:25","pubTimestamp":1780493128,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)公布，公司于2026年6月1日(美国东部时间)根据2024年股权激励计划授出5000份受限制股份单位。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1449832.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ZLAB","BK4139","LU2488822045.USD","09688","BK1161","BK4588","BK4585","BK4548","BK1574","BK1588","BK4526","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638582374","title":"547万美元年薪总裁匆匆离场，再鼎医药发生了什么？","url":"https://stock-news.laohu8.com/highlight/detail?id=2638582374","media":"华夏时报网","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638582374?lang=zh_cn&edition=full","pubTime":"2026-05-25 11:44","pubTimestamp":1779680649,"startTime":"0","endTime":"0","summary":"5月22日，再鼎医药（09688.HK）一则公告引发市场高度关注——公司总裁兼首席运营官JoshSmiley将不再担任现任职务，自5月18日起生效，最后任职日期为5月22日。颇为耐人寻味的是，从董事会作出决定到这位“二把手”正式离场，仅间隔4天。公告同时提及，Smiley需签署一份“常规的解除协议”后方可获得遣散补偿。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605253747976870.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605253747976870.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4139","09688","ZLAB","LU2488822045.USD","BK1161","BK4526","BK4531","BK4588","BK1574","BK4585","BK4548","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637653033","title":"再鼎医药(09688)：Josh Smiley不再担任公司总裁兼首席运营官","url":"https://stock-news.laohu8.com/highlight/detail?id=2637653033","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637653033?lang=zh_cn&edition=full","pubTime":"2026-05-22 08:25","pubTimestamp":1779409550,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于2026年5月21日(美国东部时间)╱2026年5月22日(上海及香港时间)向美国证券交易委员会(SEC)递交了一份表格8-K，有关本公司董事会决定 Josh Smiley 先生将不再担任本公司总裁兼首席运营官，自2026年5月18 日起生效，其在本公司的最后任职日期为2026年5月22日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1444837.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"再鼎医药(09688)：Josh Smiley不再担任公司总裁兼首席运营官","news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK4139","BK1161","BK4548","BK4588","09688","BK1588","LU2488822045.USD","ZLAB","BK4526","BK1574","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635033220","title":"再鼎医药(ZLAB)逆市上涨1.52% zoci近日获美国FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2635033220","media":"金吾财讯","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635033220?lang=zh_cn&edition=full","pubTime":"2026-05-15 22:40","pubTimestamp":1778856000,"startTime":"0","endTime":"0","summary":"金吾财讯 |再鼎医药 逆市上涨1.52%，最新报20.64美元，成交额774.69万美元。消息面上，再鼎医药官微日前宣布，美国食品药品监督管理局已授予具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。此外，高盛新近披露，已于5月8日以每股均价15.09港元场外增持再鼎医药545.57万股H股股份，价值约8,232.65万港元。增持后，高盛最新持股数目为7,070.61万股股份，好仓比例由5.75%升至6.23%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20250107/NWIzNTQyNTc0Mjc1MDI=.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NWIzNTQyNTc0Mjc1MDI=.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300518","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09688","BK4588","BK4139","BK1161","BK1574","BK4526","BK4585","LABU","ZLAB","BK4531","BK4548","LU2488822045.USD","BK1588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635700344","title":"港股异动 | 再鼎医药(09688)尾盘涨超5% zoci获FDA快速通道资格认定 用于治疗肺外神经内分泌癌","url":"https://stock-news.laohu8.com/highlight/detail?id=2635700344","media":"智通财经网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635700344?lang=zh_cn&edition=full","pubTime":"2026-05-15 15:50","pubTimestamp":1778831448,"startTime":"0","endTime":"0","summary":"再鼎医药(09688)尾盘涨超5%，截至发稿，涨4.89%，报16.1港元，成交额2.47亿港元。","market":"sg","thumbnail":"https://img.zhitongcaijing.com/image/20260515/20260515155119_66712.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20260515/20260515155119_66712.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1442173.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["VXUS","BK1574","BK4531","BK4526","BK4548","BK4588","BK4139","ZLAB","BK1161","09688","BK1588","LU2488822045.USD","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634299314","title":"再鼎医药(09688)：授出购股权及受限制股份单位","url":"https://stock-news.laohu8.com/highlight/detail?id=2634299314","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634299314?lang=zh_cn&edition=full","pubTime":"2026-05-12 16:34","pubTimestamp":1778574847,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药(09688)发布公告，公司于授出日期根据2024年股权激励计划授出13.68万份购股权(以美国存托股份计)、7.53万份受限制股份单位(以美国存托股份计)。所授出购股权涉及的相关股份数目：1,368,190;所授出受限制股份单位涉及的相关股份数目：752,880。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440675.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1588","BK4526","BK4585","ZLAB","BK4588","BK1161","BK4531","LU2488822045.USD","BK4548","BK1574","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634250452","title":"港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2634250452","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634250452?lang=zh_cn&edition=full","pubTime":"2026-05-12 10:55","pubTimestamp":1778554548,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，再鼎医药早盘涨超5%，截至发稿，涨2.38%，报15.49港元，成交额7370.89万港元。消息面上，5月11日，据再鼎医药官微消息，公司宣布，美国食品药品监督管理局已授予具有同类首创潜力的靶向Delta样配体3的抗体药物偶联物zocilurtatug pelitecan快速通道资格认定，用于治疗在接受一线标准治疗后出现疾病进展的epNECs。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1440550.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 再鼎医药(09688)早盘涨超5% zoci获FDA快速通道资格认定","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK4588","BK1119","09688","LU2488822045.USD","BK1574","BK4585","ZLAB","BK4531","BK1161","BK4548","BK4139","BK4526"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109751999","title":"异动解读 | 再鼎医药盘中大涨10.56%，自研药物Zoci获FDA快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=1109751999","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1109751999?lang=zh_cn&edition=full","pubTime":"2026-05-11 23:44","pubTimestamp":1778514241,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中股价大幅上涨10.56%，引起了市场的广泛关注。该疾病为侵袭性强、预后差的恶性肿瘤，目前全球尚无获批的靶向疗法与标准治疗方案，存在巨大的未满足医疗需求。此外，在2026年AACR年会上公布的Ib/II期注册研究数据显示，Zoci用于多线治疗失败的epNEC患者，客观缓解率达到38.2%，且安全性可控。目前，Zoci针对epNEC的临床项目正在推进注册，并已与药监部门沟通注册计划。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162641298","title":"异动解读 | 再鼎医药自研药物Zoci获FDA快速通道资格，盘前大涨6.45%","url":"https://stock-news.laohu8.com/highlight/detail?id=1162641298","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1162641298?lang=zh_cn&edition=full","pubTime":"2026-05-11 20:05","pubTimestamp":1778501135,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘前股价大涨6.45%，引起了市场的广泛关注。据悉，epNECs为侵袭性强、预后差的恶性肿瘤，全球约10万人患病，目前无获批靶向疗法与标准治疗方案，存在巨大未满足医疗需求。此外，2026年AACR年会公布的Ib/II期注册研究显示，Zoci用于多线治疗失败的epNEC患者，客观缓解率达38.2%，且安全性可控。目前Zoci的epNEC临床项目正推进注册，已与药监部门沟通注册计划。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634285739","title":"再鼎医药(ZLAB)自研药物Zoci获美国FDA授予快速通道资格","url":"https://stock-news.laohu8.com/highlight/detail?id=2634285739","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634285739?lang=zh_cn&edition=full","pubTime":"2026-05-11 19:36","pubTimestamp":1778499399,"startTime":"0","endTime":"0","summary":"据悉，epNECs为侵袭性强、预后差的恶性肿瘤，全球约10万人患病，无获批靶向疗法与标准治疗方案，存在巨大未满足医疗需求。此前2025年5月，Zoci已获FDA快速通道资格，用于广泛期小细胞肺癌治疗。此外，2026年AACR年会公布的Ib/II期注册研究显示，Zoci用于多线治疗失败的epNEC患者，客观缓解率达38.2%，且安全性可控，仅中性粒细胞减少为唯一≥3级且多例出现的治疗相关不良反应。目前Zoci的epNEC临床项目正推进注册，已与药监部门沟通注册计划。","market":"nz","thumbnail":"https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZmFlOWFhNTNlYzgzMTc4NTEyNzIzMzYzNzY2.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300251","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4548","BK4588","BK1574","BK1161","BK4526","BK1588","09688","BK4585","LABU","LU2488822045.USD","ZLAB","BK4531"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634477601","title":"大行评级丨大摩：下调再鼎医药港股目标价至19港元，维持“增持”评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2634477601","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634477601?lang=zh_cn&edition=full","pubTime":"2026-05-11 14:07","pubTimestamp":1778479621,"startTime":"0","endTime":"0","summary":"摩根士丹利发表研报，更新对再鼎医药的风险回报评估，将港股目标价由19.5港元下调至19港元，维持“增持”评级。该行根据首季趋势调整了则乐(Zejula)及瑞普替尼(repotrectinib)的销售预测，导致2026年至2028年的收入预测下调5%。大摩预测再鼎医药2026年收入为4.88亿美元，研发开支2.34亿美元，销售开支2.93亿美元；将2026年至2028年每股盈利亏损预测由0.16、0.10及0.07美元，修订为0.18、0.12及0.08美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260511/32214732.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["VXUS","EWH","09688","ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634247289","title":"大行评级丨中银国际：再鼎医药首季业绩疲弱，H股目标价大幅下调至17港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2634247289","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634247289?lang=zh_cn&edition=full","pubTime":"2026-05-11 13:37","pubTimestamp":1778477821,"startTime":"0","endTime":"0","summary":"中银国际发表研报指，再鼎医药首季业绩疲弱，收入同比下降6%至9960万美元，低于市场预期9%，主要受到则乐降幅超预期以及艾加莫德医保降价影响。持续加大的研发投入导致净亏损扩大至5100万美元。管理层预计2026年剩余时间收入将逐渐改善，但全年增长仍将受压，恢复增长预计要到2027年。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260511/32214697.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["ZLAB","09688","EWH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179031134","title":"异动解读 | 财报不及预期叠加核心产品收入下滑，再鼎医药盘中大跌5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179031134","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179031134?lang=zh_cn&edition=full","pubTime":"2026-05-09 00:28","pubTimestamp":1778257718,"startTime":"0","endTime":"0","summary":"再鼎医药今日盘中大跌5.08%，引发了市场的广泛关注。消息面上，公司此前公布的2026年第一季度财报显示，总收入为9960万美元，同比下滑6%，产品收入净额同比下降10%。具体来看，公司赖以起家的核心产品则乐受集采后医院用药模式变化影响，收入出现显著下降；另一款产品卫伟迦也因医保续约降价而出现小幅下滑。此外，公司近期宣布由王轶喆博士负责商业化工作，商业化团队换帅的时点与业绩波动叠加，引发了市场对于公司治理是否稳定的疑虑。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["ZLAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633699433","title":"创新管线即将步入密集催化阶段，探寻再鼎医药（09688）否极泰来的“三张底牌”","url":"https://stock-news.laohu8.com/highlight/detail?id=2633699433","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633699433?lang=zh_cn&edition=full","pubTime":"2026-05-08 16:07","pubTimestamp":1778227661,"startTime":"0","endTime":"0","summary":"5月7日，再鼎医药交出2026年一季报：总收入9960万美元，同比下滑6%，产品收入净额同比下降10%。乍看之下，这是一份“不及预期”的成绩单。但从2025年下半年开始，再鼎的内部重心已经发生了根本性转移。未来一年管线“催化剂密集”如果说商业化是再鼎的“底盘”，那么全球研发管线就是它的“发动机”。总结来看，当前再鼎的股价大跌之后，依旧握有三张清晰的底牌：第一张牌：全球管线的“硬核数据”。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439509.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4139","BK1588","BK4548","BK4588","BK4526","BK4585","LU2488822045.USD","BK1161","BK4531","ZLAB","BK1574","09688"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633147905","title":"再鼎医药(09688)第一季度总收入为9960万美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2633147905","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633147905?lang=zh_cn&edition=full","pubTime":"2026-05-07 20:45","pubTimestamp":1778157937,"startTime":"0","endTime":"0","summary":"智通财经APP讯，再鼎医药 发布公告，2026年第一季度总收入为9960万美元，2025年同期为1.065亿美元，同比下降6%，2026年第一季度产品收入净额为9560万美元，2025年同期为1.057亿美元，同比下降10%，按固定汇率计算同比下降12%。2026年第一季度亏损净额为5100万美元，归属于普通股股东的每股普通股亏损为0.05美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1439233.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1588","BK1161","BK1574","BK4526","BK4588","09688","BK4585","BK4548","ZLAB","BK4139","BK4531","LU2488822045.USD"],"isVideo":false,"video":null,"gpt_icon":1}],"profile":{"websiteUrl":"http://www.zailaboratory.com","stockEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":0.1984},{"period":"3month","weight":-0.0477},{"period":"6month","weight":0.0647},{"period":"1year","weight":-0.4347},{"period":"ytd","weight":0.1196}],"compareEarnings":[{"period":"1week","weight":-0.0005},{"period":"1month","weight":0.0084},{"period":"3month","weight":0.0963},{"period":"6month","weight":0.074},{"period":"1year","weight":0.2016},{"period":"ytd","weight":0.0931}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"再鼎医药有限公司是一家主要从事生物制药业务的控股公司。该公司致力于通过产品的发现、开发和商业化解决肿瘤、免疫、神经科学和感染性疾病领域未被满足的医疗需求。该公司拥有从发现阶段到临床项目后期的一系列专利候选药物，其中包括“则乐”、“OPTUNE”、“擎乐”、“纽再乐”及“卫伟迦”等。该公司在国内市场和海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.085823},{"month":2,"riseRate":0.555556,"avgChangeRate":0.030708},{"month":3,"riseRate":0.222222,"avgChangeRate":-0.076257},{"month":4,"riseRate":0.444444,"avgChangeRate":0.02394},{"month":5,"riseRate":0.444444,"avgChangeRate":0.004882},{"month":6,"riseRate":0.555556,"avgChangeRate":0.07528},{"month":7,"riseRate":0.555556,"avgChangeRate":0.008766},{"month":8,"riseRate":0.625,"avgChangeRate":0.000651},{"month":9,"riseRate":0.375,"avgChangeRate":-0.055585},{"month":10,"riseRate":0.444444,"avgChangeRate":-0.047464},{"month":11,"riseRate":0.555556,"avgChangeRate":0.101421},{"month":12,"riseRate":0.444444,"avgChangeRate":-0.029495}],"exchange":"NASDAQ","name":"再鼎医药","nameEN":"Zai Lab Ltd"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"再鼎医药,ZLAB,再鼎医药股票,再鼎医药股票老虎,再鼎医药股票老虎国际,再鼎医药行情,再鼎医药股票行情,再鼎医药股价,再鼎医药股市,再鼎医药股票价格,再鼎医药股票交易,再鼎医药股票购买,再鼎医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"再鼎医药(ZLAB)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供再鼎医药(ZLAB)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}